Table 3 Distribution of IDH1 mutation and MGMT methylation status among GBM cases
From: Clinical impact of IDH1 mutations and MGMT methylation in adult glioblastoma
Factors | IDH1 mutant | MGMT methylated (≥ 66%) |
|---|---|---|
Age (Mean) | ||
< 60 ψεαρσ | 11 (73.3%) | 24 (8%) |
≥ 60 years | 4 (26.7%) | 6 (20%) |
X2 = 7.7, P = 0.005 | ||
Gender | ||
Male | 8 (53.3%) | 16 (53.3%) |
Female | 7 (46.7) | 14 (46.7) |
ECGO | ||
< 2 | 11 (73.3%) | 19 (63.3%) |
2 | 4 (26.7%) | 11 (36.7%) |
X2 = 15, P < 0.0001 | X2 = 26, P < 0.0001 | |
Tumor site | ||
Lt | 8 (53.3%) | 17 (56.7%) |
Right | 7 (46.7) | 13 (43.3%) |
Multiple | 0 (0%) | 0 (0%) |
X2 = 7.2, P = 0.027 | ||
Tumor size | ||
< 5χμ | 7 (46.7) | 17 (56.7%) |
≥ 5 cm | 8 (53.3%) | 13 (43.3%) |
X2 = 9.3, P = 0.002 | ||
Surgical intervention | ||
Biopsy | 8 (53.3%) | 13 (43.3%) |
Resection | ||
Total | 4 (26.7%) | 14 (46.7%) |
Sub-total | 3 (20%) | 3 (10%) |
X2 = 9, P = 0.011 | X2 = 9.98, P = 0.007 | |